Chronic Myelogenous Leukemia in the Age of Targeted Therapy: Recommendations From an Expert Panel Credits Available Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)" for physicians This program is based on a discussion by an expert panel convened at the American Society of Hematology Meeting, December 7, 2007, in Atlanta, Georgia...
Sequencing of ancient corn landraces to Maize was first domesticated in the highlands of Mexico about 10,000 years ago and is now one of the most important crop plants in the world.It is a member of the grass family, which also hosts the world's other major crops including rice...
Ancient Mexican Maize Varieties: Sequencing Of Ancient Corn Landraces To Ensure Genetic Diversity And Resource Maize was first domesticated in the highlands of Mexico about 10,000 years ago and is now one of the most important crop plants in the world.It is a member of the grass family, which also hosts the world's other major crops including rice...
Oil Rises, Dow Falls - Fast Money Recap (6/26/08) L / ANR / C / COF / COP / CSCO / FCX / GM / GS / HAL / IBM / JPM / LLL / MER / MRK / MS / NUE / ORCL / QID / RIMM / SMH / SU / TXN / USO / UUP Font Size: Print Wall Street Storm: Citigroup (C), Morgan Stanley (MS), GM (GM), Merrill Lynch ...
Ancient Mexican maize varieties EUREKALERT Contact: Dr.Jean-Philippe Vielle-Calzada 462-623-9634 Sequencing of ancient corn landraces to ensure genetic diversity and resources Maize was first domesticated in the highlands of Mexico about 10,000 years ago and is now one...
60 hands to celebrate 60 years The Royal College of Nursing has made its mark in the history of Nottinghams two main hospitals by taking part in a novel 60th anniversary celebration of the NHS.Sixty people aged between one and 60 were invited by Nottingham University...
Frontline Dasatinib Demonstrates Rapid Response in Patients With Previously Untreated Chronic-Phase Chronic My Recent news - Chronic Myeloid Leukemia (CML) Dasatinib Benefits Children and Adolescents With Relapsed or Refractory Leukaemia: Presented at EHA- (DGDispatch) High-Dose Imatinib Offers No Additional Benefit to Standard Dose as First-Line...
Cort Johnson Interviews ME/CFS Victor Martha Kilcoyne _ Cort Johnson Interviews ME/CFS Victor Martha Kilcoyne.
New data shows Glivec 800 mg dose more effective than 400 mg dose in initial treatment New data from a large, international clinical trial find that patients with newly diagnosed chronic myeloid leukaemia who received Glivec (imatinib) at 800 mg/day as their initial treatment achieved clinical milestones significantly faster...
High-Dose vs Standard-Dose Imatinib in Treatment-Naive Patients With Newly Diagnosed CML: Presented at EHA my personal edition> chronic myeloid leukemia (cml) > news E-Mail this DGDispatch to a colleague DGDispatch COPENHAGEN, Denmark -- June 15, 2008 -- High-dose versus standard-dose imatinib induces rapid responses and a trend...
Bosutinib Induces Response in Patients With CML Resistant or Intolerant to Imatinib, Other TKIs: Presented at my personal edition> chronic myeloid leukemia (cml) > news E-Mail this DGDispatch to a colleague DGDispatch COPENHAGEN, Denmark -- June 15, 2008 -- Bosutinib has demonstrated efficacy and a good tolerability profile in patients...
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Ac Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current CML and ALL Therapies COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc.today reported preliminary phase 1 data from an ongoing trial of XL228...
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Ac COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc.today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute...
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chr - Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Gleevec as standard of care EAST HANOVER, N.J., June 13 /PRNewswire/ -- New data from a large, international clinical...
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Ac Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current CML and ALL Therapies COPENHAGEN, Denmark, June 13, 2008 /PRNewswire-FirstCall/ -- Exelixis, Inc.today reported preliminary phase 1 data from an ongoing trial of...
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Ac Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current CML and ALL Therapies COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc.today reported preliminary phase 1 data from an ongoing trial of XL228...
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chr - Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Gleevec as standard of care EAST HANOVER, N.J., June 13 /PRNewswire/ -- New data from a large, international clinical...
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Ac Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current CML and ALL Therapies COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc.today reported preliminary phase 1 data from an ongoing trial of XL228...
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Ac COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc.(Nasdaq: EXEL) today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome...
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, (News) Inc.today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive...
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Ac COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc.(Nasdaq: EXEL) today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome...
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chr - Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Gleevec as standard of care EAST HANOVER, N.J., June 13, 2008 /PRNewswire/ -- New data from a large, international...
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chr - Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Gleevec as standard of care EAST HANOVER, N.J., June 13 /PRNewswire/ -- New data from a large, international clinical...
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chr , 4:00 AM EST The Tyrosine Kinase Inhibitor Optimization and Selectivity Study (TOPS) is the first Phase III, randomized, controlled clinical trial designed to evaluate the potential benefits of an 800 mg starting dose across all risk...
Novartis: Gleevec High Dose Study Doesn't Meet Goal Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Swiss drugmaker Novartis AG (NVS) said Friday a new study failed to meet its primary goal of showing that patients will benefit from starting treatment with a higher-than-the-standard dose of blood...
